The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.10, FiscalAI reports. Veracyte raised its 2026 revenue outlook to $590 million-$596 million, reflecting 14%-15% growth, while maintaining adjusted EBITDA guidance above 26%. Veracyte Price PerformanceShares of Veracyte stock traded up $4.07 during trading on Thursday, hitting $59.78. Also, CEO Marc Stapley sold 138,051 shares of Veracyte stock in a transaction that occurred on Thursday, June 4th. Over the last three months, insiders have sold 206,696 shares of company stock valued at $10,079,058.